Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | solute carrier family 13 (sodium-dependent citrate transporter), member 5 | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0107 | 1 | 1 |
Leishmania major | sodium/sulphate symporter, putative | 0.0107 | 1 | 0.5 |
Echinococcus multilocularis | solute carrier family 13 | 0.0107 | 1 | 0.5 |
Trypanosoma cruzi | Low-affinity phosphate transporter PHO91 | 0.0059 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0107 | 1 | 1 |
Trichomonas vaginalis | Inorganic phosphate transporter, putative | 0.0107 | 1 | 1 |
Echinococcus multilocularis | solute carrier family 13 | 0.0107 | 1 | 0.5 |
Echinococcus granulosus | solute carrier family 13 | 0.0107 | 1 | 0.5 |
Echinococcus granulosus | solute carrier family 13 | 0.0107 | 1 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0107 | 1 | 1 |
Trichomonas vaginalis | sodium-dependent high-affinity dicarboxylate transporter, putative | 0.0107 | 1 | 1 |
Schistosoma mansoni | sodium/dicarboxylate cotransporter-related | 0.0107 | 1 | 1 |
Echinococcus granulosus | solute carrier family 13 | 0.0107 | 1 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0107 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 1 | 0.5 |
Trichomonas vaginalis | Inorganic phosphate transporter, putative | 0.0107 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0107 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0107 | 1 | 1 |
Echinococcus multilocularis | solute carrier family 13 | 0.0107 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
FC (functional) | = 10 | Increase in urinary citrate output in C57BL/6J mouse at 250 mg/kg, po measured after 7 hrs by UPLC-MS/MS analysis | ChEMBL. | 26734723 |
IC50 (binding) | = 4.8 | Inhibition of NaCT in human hepatocytes assessed as [14C]-citrate uptake after 30 mins by scintillation counting method | ChEMBL. | 26734723 |
IC50 (binding) | = 6.3 | Inhibition of NaCT (unknown origin) expressed in HEK293 cells assessed as inhibition of [14C]citrate uptake by microbeta plate reader analysis | ChEMBL. | 26734723 |
IC50 (binding) | = 0.41 uM | Inhibition of NaCT (unknown origin) expressed in HEK293 cells assessed as inhibition of [14C]citrate uptake by microbeta plate reader analysis | ChEMBL. | 26734723 |
IC50 (binding) | = 16.2 uM | Inhibition of NaCT in human hepatocytes assessed as [14C]-citrate uptake after 30 mins by scintillation counting method | ChEMBL. | 26734723 |
IC50 (binding) | > 100 uM | Inhibition of NaDC3 (unknown origin) expressed in HEK293 cells assessed as inhibition of [14C]citrate uptake by microbeta plate reader analysis | ChEMBL. | 26734723 |
IC50 (binding) | > 100 uM | Inhibition of NaDC1 (unknown origin) expressed in HEK293 cells assessed as inhibition of [14C]citrate uptake by microbeta plate reader analysis | ChEMBL. | 26734723 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.